BLACK WEEKSViale −15 % · kompleti −10 % · ostalo −5 %s kodoBrezplačna dostava v Nemčiji od 200 €

Ta stran je bila prevedena samodejno in lahko vsebuje napake. Ste materni govorec? Veseli bomo vaših povratnih informacij in popravkov.Pošljite povratne informacije

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), fotografija izdelka

Laboratorijsko poročilo

PDF
Testirano
Testirano
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Laboratorij
Analiza Białek
Datum
October 2026
Rezultat
20.34 mg per tablet (20 mg label)
Št. naročila
Geslo

Neodvisno testirano, preverljivo z geslom neposredno pri laboratoriju.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Naročilo

Cena na kos - Brezplačna dostava v Nemčiji od 200 € med Black Weeks
  • DHL s sledenjem
  • Diskretna embalaža

4.6 od 5 na Trustpilotu73 ocen

Na prvi pogled

Tamoxifen (Nolvadex) v številkah

Ključni podatki iz našega leksikona.

Celoten vnos v leksikonu
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Znanje

Vse o Tamoxifen (Nolvadex)

Podrobne informacije bodo kmalu na voljo.

Odmerjanje

Nalaganje podatkov o odmerjanju …

Več v leksikonu

FAQ

Pogosta vprašanja

Viri za vsak odgovor: vnos v leksikonu

Imate še vprašanje?

Pišite nam, naša ekipa vam bo pomagala.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Primerjave

Primerjava

Sorodno

Sorodni izdelki